The long-term objectives of my research are to understand the detailed mechanisms of mitochondrial biogenesis at the level of enzyme structure and function as well as at the level of mtDNA organization and expression. The specific goal of this proposal is to begin to elucidate the roles of DNA topoisomerases in the replication and metabolism of mtDNA. In particular, the interaction of ATP with nuclear and mitochondrial type I topoisomerase will be investigated. It has been shown that the ATP-independent type I topoisomerase is actually inhibited by ATP. Since this effect has been observed with topos from human leukemia, HeLA and calf thymus cells, we hypothesize that this ATP regulation of topo I activity may be a general phenomenon in mammalian cells. The details of the nucleotide-enzyme interaction as well as the mechanism of this regulation using in vivo and in vitro studies will be elucidated. The role of these enzymes in mitochondrial DNA replication and metabolism will be defined by investigating the interactions of topoisomerase I and II with the mitochondrial genome in vivo and in vitro. These studies will utilize several antitumor drugs which have been shown to specifically interfere with the topoisomerase- catalyzed strand breaking and rejoining process such that, in the presence of a protein denaturant, DNA cleavage results with topoisomerase covalently attached to the end of the DNA fragment. In particular, camptothecin will be used to probe for topo I-DNA interactions, and 4'- (9-acridinylamin)-methane sulfon-m-anisidide (mAMSA) and the epipodophyllotoxins VP-16 and VM-26 will be used to prove topo II-DNA interactions. These studies should elucidate some of the details of the involvement of topo I and topo II in replication and expression of the mitochondrial genome. Regulation of topoisomerase activity is of general significance but as detailed in the proposal, the maintenance of proper chromosomal and extrachromosomal DNA superhelicity is important in carcinogenesis, mutagenesis and tumorigenesis and as such these studies are relevant to problems in cancer etiology and therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
7R01GM037106-02
Application #
3292119
Study Section
Physiological Chemistry Study Section (PC)
Project Start
1988-09-01
Project End
1991-02-28
Budget Start
1988-09-01
Budget End
1989-02-28
Support Year
2
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Eastern Virginia Medical School
Department
Type
Schools of Medicine
DUNS #
City
Norfolk
State
VA
Country
United States
Zip Code
23501
Topcu, Z; Castora, F J (1995) Mammalian mitochondrial DNA topoisomerase I preferentially relaxes supercoils in plasmids containing specific mitochondrial DNA sequences. Biochim Biophys Acta 1264:377-87
Lin, J H; Castora, F J (1995) Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m-AMSA. Arch Biochem Biophys 324:293-9
Staub, J M; Castora, F J (1993) Mammalian mitochondrial DNA sequences can function as in vivo bacterial transcription terminators. Biochem Biophys Res Commun 192:616-26
Ciavarra, R P; Duvall, W; Castora, F J (1992) Induction of thermotolerance in T cells protects nuclear DNA topoisomerase I from heat stress. Biochem Biophys Res Commun 186:166-72
Lin, J H; Lazarus, G M; Castora, F J (1992) DNA topoisomerase I from calf thymus mitochondria is associated with a DNA binding, inner membrane protein. Arch Biochem Biophys 293:201-7
Castora, F J; Erickson, C E; Kovacs, T et al. (1991) 2',5'-oligoadenylates inhibit relaxation of supercoiled DNA by calf thymus DNA topoisomerase I. J Interferon Res 11:143-9
Lin, J H; Castora, F J (1991) DNA topoisomerase II from mammalian mitochondria is inhibited by the antitumor drugs, m-AMSA and VM-26. Biochem Biophys Res Commun 176:690-7
Staub, J M; Castora, F J (1990) Identification of transcription promoter regions from rat mtDNA that are utilized in vivo by the bacterial RNA polymerase. Biochem Biophys Res Commun 172:1282-90